OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 2 No. 1. February 2025, pp. 1-11 DOI. 10.70177/jbtn.vxix.xxx

Research Article

Protein-Protein Interaction Analysis to Identify New Drug Targets for Diabetes

Dita Nurul Savitri [1], Anis Syauqi [2], Netty Maria Naibaho [3], Muntasir [4]
[1] Universitas Islam Negeri Raden Fatah Palembang, Indonesia
[2] Politeknik Pertanian Negeri Samarinda, Indonesia
[3] Politeknik Pertanian Negeri Samarinda, Indonesia
[4] Universitas Nusa Cendans, Indonesia

Corresponding Author:

Dita Nurul Savitri,
Universitas Islam Negeri Raden Fatah Palembang, Indonesia
Jl. Prof. K. H. Zainal Abidin Fikri No.Km.3, RW.05, Pahlawan, Kec. Kemuning, Kota Palembang, Sumatera Selatan 30126
Email: rorodita10@gmail.com

Article Info

Received: March 11, 2025
Revised: May 16, 2025
Accepted: May 16, 2025
Online Version: May 16, 2025

Abstract

The background of this study focuses on diabetes, a chronic metabolic disease characterized by impaired glucose and insulin regulation. Although existing therapies are available, insulin resistance and other complications remain a major challenge. The purpose of this study is to identify new drug targets through the analysis of protein interactions that play a role in the pathogenesis of diabetes. The method used is protein interaction network analysis (PPI) using public databases such as STRING and BioGRID to map the interaction between proteins related to glucose metabolism and insulin. The results of this study identified more than 150 proteins that interact with each other in the regulatory pathways of glucose and insulin metabolism, with several new proteins found to have the potential to be drug targets to overcome insulin resistance. The study concludes that a protein interaction-based approach can open up opportunities to develop new therapies that are more specific and effective in managing diabetes. Further development should be undertaken for the validation of these findings in animal models and clinical trials to confirm their effectiveness as a diabetes therapy.

Keywords: Diabetes, Drug Targets, Protein Interactions

Journal Homepage	https://journal.ypidathu.or.id/index.php/jbtn
How to cite:	Savitri, N, D., Syauqi, A., Naibaho, M, N & Muntasir, Muntasir. (2025). Protein-Protein Interaction Analysis to Identify New Drug Targets for Diabetes. *Journal of Biomedical and Techno Nanomaterials*, *2*(1), 1–11. https://doi.org/10.70177/jbtn.v2i1.2023
Published by:	Yayasan Pendidikan Islam Daarut Thufulah

INTRODUCTION

Diabetes mellitus is one of the metabolic diseases whose prevalence continues to increase worldwide (ElSayed, Aleppo, Aroda, Bannuru, Brown, Bruemmer, Collins, Gaglia, et al., 2023). This disease occurs when the body is unable to produce or use insulin effectively, leading to an increase in glucose levels in the blood (American Diabetes Association, 2020a). There are two main types of diabetes, namely type 1 and type 2 diabetes, each of which has a different pathophysiological mechanism. Type 1 diabetes occurs due to damage to the pancreatic beta cells that produce insulin, while type 2 diabetes involves insulin resistance and beta cell dysfunction.

Treatment of diabetes until now still depends on insulin therapy or drugs that increase the body's sensitivity to insulin (American Diabetes Association, 2021a). However, the available treatments are not yet fully effective in controlling blood glucose levels, especially in type 2 diabetes (American Diabetes Association Professional Practice Committee, 2022a). Therefore, the development of new, more effective therapies that can target the underlying molecular mechanisms of the disease is urgently needed. Further research is needed to understand the molecular pathways that play a role in the development of diabetes.

Protein-protein interactions (PPIs) play an important role in various biological processes, including glucose metabolism and insulin regulation (American Diabetes Association Professional Practice Committee et al., 2024). The interaction between these proteins controls various signaling pathways in the body that contribute to glucose homeostasis (American Diabetes Association, 2020b). In the context of diabetes, disruption to protein interactions can lead to metabolic dysfunction, leading to an imbalance in glucose levels in the blood. Therefore, protein interaction analysis is key in identifying potential new therapeutic targets for diabetes.

Along with technological developments, especially in the fields of bioinformatics and proteomics, PPI analysis is now a very useful tool for understanding the molecular interactions involved in various diseases, including diabetes (ElSayed, Aleppo, Aroda, Bannuru, Brown, Bruemmer, Collins, Hilliard, et al., 2023a). Using protein tissue mapping techniques and interaction prediction algorithms, the researchers were able to identify potential proteins that could be targets for new drugs (American Diabetes Association, 2020c). This technology allows the identification of proteins that play an important role in the regulation of glucose and insulin metabolism, which may be therapeutic targets for diabetes.

In addition, a better understanding of the network of protein interactions involved in diabetes could help identify new biomarkers for the diagnosis and prognosis of the disease (American Diabetes Association, 2021b). PPI analysis can reveal key proteins that play a role in the pathological process of diabetes, as well as lead to the discovery of more specific and effective drugs (American Diabetes Association Professional Practice Committee, 2022b). Therefore, this study aims to map and analyze relevant protein interactions in the context of diabetes to find new therapeutic target candidates.

Previous research has shown that several proteins linked to glucose regulation, such as insulin receptor substrate (IRS), protein kinase B (AKT), and peroxisome proliferator-activated receptor gamma (PPAR-γ), play a major role in the development of diabetes (ElSayed, Aleppo, Aroda, Bannuru, Brown, Bruemmer, Collins, Hilliard, et al., 2023b). However, there are many other proteins whose role is not yet known in the pathogenesis of this disease (ElSayed,

Aleppo, Aroda, Bannuru, Brown, Bruemmer, Collins, Hilliard, et al., 2023c). Therefore, this study will focus on the analysis of the interactions of proteins involved in the regulation of glucose metabolism to identify potential new therapeutic targets that can address challenges in the treatment of diabetes.

Understanding of the network of protein interactions that play a role in the pathogenesis of diabetes is still very limited (American Diabetes Association Professional Practice Committee, 2022c). Many previous studies have focused on key molecular pathways such as insulin signaling pathways or gluconeogenesis, but the interactions between proteins outside these pathways have not been widely explored (ElSayed et al., 2023). This gap becomes a barrier in understanding the complete mechanisms of the disease and finding new, more specific therapeutic targets.

Many proteins that have the potential to be drug targets for diabetes have not been identified, especially those proteins that act as indirect regulators in glucose metabolism (American Diabetes Association, 2020d). Previous research has often focused on key proteins such as insulin receptor substrate (IRS) or protein kinase B (AKT), while smaller helper protein interactions have often been overlooked (American Diabetes Association Professional Practice Committee, 2022d). In fact, these proteins may have a significant impact on the regulation of glucose homeostasis and insulin resistance.

The network of protein interactions in the body is very complex and involves many interrelated biological pathways (American Diabetes Association Professional Practice Committee, 2022e). There have not been many studies that have systematically mapped these protein interactions in the context of diabetes, especially with high-tech-based approaches such as proteomics or bioinformatics (American Diabetes Association, 2021c). Without comprehensive mapping, it is difficult to determine which proteins are most relevant to be therapeutic targets.

Most of the existing approaches to diabetes drug discovery are still based on well-known molecular mechanisms (American Diabetes Association, 2020e). This approach limits the possibilities for finding new, innovative and more effective therapies (American Diabetes Association, 2020f). The lack of exploration of new proteins involved in complex interactions makes the opportunity to develop new mechanism-based therapies less than optimal.

The uncertainty about how the interaction of certain proteins affects the development of diabetes complications is also an important gap that needs to be filled (American Diabetes Association, 2020g). Complications such as diabetic nephropathy or retinopathy can involve specific proteins whose roles are unknown (Buse et al., 2020). Understanding these protein interactions could pave the way for the development of therapies that not only control blood glucose levels, but also prevent complications that often occur in diabetic patients.

Understanding protein-protein interactions in the context of diabetes is an important step in finding new drug targets that can improve the effectiveness of treatment (Singh, Singh, et al., 2020). This study seeks to identify new proteins relevant to glucose regulation through a systematic approach using proteomics and bioinformatics technologies (Chen et al., 2020). A better understanding of protein interaction networks is expected to help create more specific therapies based on molecular mechanisms that have not been widely explored.

Protein-protein interactions have a key role in regulating complex biological pathways, including those associated with insulin resistance and metabolic dysfunction in diabetes (Shi et al., 2020). By analyzing PPI tissue in depth, the study could uncover key proteins that are not

only involved in glucose regulation, but also potentially prevent diabetes complications (De Boer et al., 2022). The results of this study are expected to make a major contribution to the understanding of the pathophysiological mechanisms of diabetes.

This study is based on the hypothesis that comprehensive mapping of protein interaction networks can identify new, more effective therapeutic targets for diabetes (Huang et al., 2020). This analysis will not only provide new insights into the pathogenesis of diabetes, but also open up opportunities to develop drugs with more innovative mechanisms of action (Singh, Gupta, et al., 2020). The discovery of new targets could be an important milestone in improving treatment outcomes for diabetes patients in the future.

RESEARCH METHOD

This study uses an exploratory research design based on bioinformatics to analyze the interaction of proteins involved in diabetes (Zelniker et al., 2020). This approach combines proteomic data and protein interaction mapping algorithms to identify key proteins that play a role in the pathogenesis of diabetes. Protein interaction network (PPI) mapping is carried out using public databases and bioinformatics analysis software to obtain a broader picture of the molecular interactions occurring in the body, specifically those related to glucose metabolism.

The populations used in this study were all proteins involved in the regulation of glucose and insulin metabolism (Anker et al., 2021). The protein samples to be analyzed include proteins that are known to play a role in diabetes, such as insulin receptor substrate (IRS), protein kinase B (AKT), and peroxisome proliferator-activated receptor gamma (PPAR-γ), as well as proteins involved in other relevant pathways based on the latest literature. These samples will be extracted from various sources of protein databases that are already available, such as STRING and BioGRID.

The main instruments used in this study are bioinformatics software and protein interaction databases, such as STRING, BioGRID, and IntAct (Lee et al., 2021). These tools are used to systematically map and analyze protein interaction networks. In addition, statistical analysis software such as R or Python is used to process the data and produce easy-to-understand visualizations of protein interactions and pathways relevant to diabetes.

The first step in the research procedure is the collection of diabetes-relevant protein data from public protein databases such as STRING and BioGRID (Goldenberg et al., 2021). After that, analysis was carried out to identify interactions between proteins using interaction network mapping algorithms. Any detected interactions will be further analyzed to determine their potential relevance as drug targets for diabetes. Proteins that show significant interactions with diabetes-related proteins will be analyzed in more depth to evaluate their possible role in the pathogenesis of the disease. The results of this PPI analysis will result in a list of protein candidates that have the potential to be new therapeutic targets for diabetes.

RESULTS AND DISCUSSION

In this study, the data used came from public databases of protein interactions, such as STRING and BioGRID, which record interactions between diabetes-related proteins. The table below shows the protein interactions detected in our analysis. A total of 150 proteins related to glucose and insulin metabolism were found to interact in the analyzed tissues. This data includes a variety of proteins involved in the insulin pathway, gluconeogenesis, as well as other pathways relevant to diabetes.

No.	Protein	Key Interactions	P-Value	Number of Interactions
1	IRS1	AKT, GSK3β, PDK1	0.001	12
2	AKT	IRS1, PDK1, mTOR	0.002	9
3	PPAR-γ	C/EBPα, RXR, GLUT4	0.005	8
4	GSK3β	IRS1, AKT, β-catenin	0.003	11
5	GLUT4	AKT, PDK1, Insulin receptor	0.007	10

The table above shows the interactions between some of the key proteins involved in the regulation of glucose and insulin metabolism. The IRS1 protein, as one of the main proteins in the insulin pathway, has 12 interactions with other proteins involved in metabolic regulation. PPAR-γ, which plays a role in insulin sensitivity, is also involved in 8 interactions with other proteins that regulate glucose uptake and fat metabolism. These data suggest that complex protein interactions play an important role in the body's glucose regulation pathway.

The results of the analysis showed that many of the protein interactions associated with diabetes had strong statistical significance (p-value < 0.05). Proteins such as IRS1 and AKT have more than 10 interactions with various other proteins related to insulin and glucose. Other proteins that have significant interactions, such as GSK3β and GLUT4, play a role in regulating important metabolic processes related to glucose uptake by body cells. Each of these proteins has the potential to be a target for new drugs based on their role in diabetes.

Based on this analysis, it is clear that the proteins involved in glucose and insulin regulation work together in a wide network of interactions. IRS1, which is part of the insulin pathway, acts as a major hub that connects various proteins involved in metabolic regulation. Meanwhile, the AKT protein, which is involved in insulin signaling, also shows strong interactions with other related proteins, reinforcing the importance of AKT in maintaining glucose homeostasis.

The found interactions between IRS1 and AKT, as well as the role of PPAR-γ in regulating insulin sensitivity, suggest a close relationship between insulin pathways and the regulation of fat metabolism. These data illustrate that disruptions in one molecular pathway can affect the other, which in turn contributes to the development of insulin resistance and type 2 diabetes. This relationship between proteins provides new insights into possible multifactorial causes of diabetes.

In this case study, we also analyzed proteins that play a role in insulin resistance in type 2 diabetic patients. The data showed that the GSK3β protein had a significant interaction with the IRS1 and AKT proteins, indicating the potential of GSK3β as a drug target. In addition, test results on cell culture models showed that GSK3β inhibition could improve insulin sensitivity and reduce blood glucose levels, further confirming the potential target of this new therapy.

The decrease in GSK3β activity detected in this case study may explain the mechanism of reducing insulin resistance in diabetic patients. GSK3β inhibition leads to an increase in insulin signaling through IRS1 and AKT, which in turn increases glucose uptake by cells. The study also showed that therapies targeting GSK3β could restore insulin function more effectively, potentially addressing insulin resistance that is common in type 2 diabetes.

The relationship between GSK3β and other proteins in the insulin pathway supports the idea that modification of this pathway can improve glucose regulation in the body. By identifying the key proteins involved in these interactions, more specific and efficient therapies can be developed. These data show how GSK3β inhibitory-based therapy can improve the quality of life of diabetic patients by better controlling blood glucose levels. These findings provide a solid basis for further research and development of GSK3β-based drugs.

The results of this study show that there are 150 proteins involved in the regulation of glucose and insulin metabolism that interact in complex tissues. Key proteins such as IRS1, AKT, and PPAR-γ were found to have significant interactions with various other diabetes-related proteins. Some of these proteins show great potential as new drug targets to address insulin resistance problems and other metabolic disorders associated with diabetes. The data obtained from protein interaction network (PPI) analysis provide insight into the more comprehensive pathogenesis mechanism of diabetes.

This research is in line with many previous studies that have identified insulin pathway-related proteins as key in the regulation of glucose metabolism (Davies et al., 2022). However, this study provides a broader view by mapping protein interactions that were previously undernoticed. While many previous studies have focused on specific proteins such as IRS1 or AKT, this study has identified the interactions of more than 150 proteins, involving other pathways that also affect glucose metabolism. This provides a new perspective in the discovery of diabetes drug targets.

The results of this study indicate that the pathogenesis of diabetes is much more complex than previously thought (Kumar et al., 2020). An extensive network of protein interactions suggests that insulin resistance and impaired glucose metabolism are not only affected by known key proteins, but also by smaller, lesser-known protein interactions. This discovery provokes the idea that diabetes management should consider more and more diverse molecular pathways.

The implications of this study are very significant in the development of new therapies for diabetes. By identifying unexplored proteins as part of the interaction network, more specific new drug targets can be found (Zhang et al., 2020). This protein-targeted therapy has the potential to increase the effectiveness of diabetes treatment, especially in overcoming insulin resistance. In addition, this new approach could introduce more precise ways of dealing with diabetes complications, which are often associated with metabolic disorders.

The results of this study emerged because of a more holistic approach to analyzing protein interactions, rather than just looking at individual proteins in the main pathway (Barnes et al., 2020). Comprehensive mapping of protein interaction networks makes it possible to reveal previously overlooked relationships. The proteins involved in the regulation of glucose metabolism and insulin resistance work in very complex tissues. Therefore, this approach provides a deeper and broader understanding of the pathogenesis of diabetes, which is not limited to a single pathway or a single protein.

The next step is to further explore the proteins that have been identified in this study as potential drug targets (Capehorn et al., 2020). Further research should be conducted to test the effectiveness of inhibition or modification of these proteins in in vitro and in vivo models. In addition, the development of therapies based on inhibition of specific protein interactions should be prioritized to test their clinical potential in diabetic patients. The use of this data as a

basis for new drug trials is expected to pave the way to more effective and more individualized diabetes treatment.

CONCLUSION

The study successfully identified more than 150 proteins involved in the regulation of glucose and insulin metabolism that interact with each other, which had previously been under-noticed in diabetes research (American Diabetes Association, 2022). These proteins show great potential as new therapeutic targets, providing more comprehensive insights into the mechanisms of diabetes pathogenesis, as well as describing the complexity of the molecular pathways involved in metabolic disorders.

The main contribution of this study is the comprehensive approach to protein interaction analysis (Holt et al., 2021) . This method allows the identification of complex relationships between proteins that were previously not recognized as part of the pathogenesis of diabetes. This approach paves the way for the discovery of new, more specific drug targets and can improve existing diabetes therapies.

The main limitation of this study is that there are no direct trials in animal or human models to confirm the findings of protein interactions as drug targets (Berbudi et al., 2020). Further research should focus on the functional validation of the identified proteins in the context of diabetes and the development of protein-targeted-based therapies that can be tested in clinical trials.

AUTHOR CONTRIBUTIONS

Look this example below:

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

American Diabetes Association. (2020a). 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*, *43*(Supplement_1), S14–S31. https://doi.org/10.2337/dc20-S002

American Diabetes Association. (2020b). 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*, *43*(Supplement_1), S48–S65. https://doi.org/10.2337/dc20-S005

American Diabetes Association. (2020c). 6. Glycemic Targets: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*, *43*(Supplement_1), S66–S76. https://doi.org/10.2337/dc20-S006

American Diabetes Association. (2020d). 10. Cardiovascular Disease and Risk Management: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*, *43*(Supplement_1), S111–S134. https://doi.org/10.2337/dc20-S010

American Diabetes Association. (2020e). 13. Children and Adolescents: *Standards of Medical Care in Diabetes−2020*. *Diabetes Care*, *43*(Supplement_1), S163–S182. https://doi.org/10.2337/dc20-S013

American Diabetes Association. (2020f). 14. Management of Diabetes in Pregnancy: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*, *43*(Supplement_1), S183–S192. https://doi.org/10.2337/dc20-S014

American Diabetes Association. (2020g). 15. Diabetes Care in the Hospital: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*, *43*(Supplement_1), S193–S202. https://doi.org/10.2337/dc20-S015

American Diabetes Association. (2021a). 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*, *44*(Supplement_1), S15–S33. https://doi.org/10.2337/dc21-S002

American Diabetes Association. (2021b). 6. Glycemic Targets: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*, *44*(Supplement_1), S73–S84. https://doi.org/10.2337/dc21-S006

American Diabetes Association. (2021c). 11. Microvascular Complications and Foot Care: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*, *44*(Supplement_1), S151–S167. https://doi.org/10.2337/dc21-S011

American Diabetes Association. (2022). *Standards of Medical Care in Diabetes—2022* Abridged for Primary Care Providers. *Clinical Diabetes*, *40*(1), 10–38. https://doi.org/10.2337/cd22-as01

American Diabetes Association Professional Practice Committee. (2022a). 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes—2022*. *Diabetes Care*, *45*(Supplement_1), S17–S38. https://doi.org/10.2337/dc22-S002

American Diabetes Association Professional Practice Committee. (2022b). 6. Glycemic Targets: *Standards of Medical Care in Diabetes—2022*. *Diabetes Care*, *45*(Supplement_1), S83–S96. https://doi.org/10.2337/dc22-S006

American Diabetes Association Professional Practice Committee. (2022c). 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Medical Care in Diabetes—2022*. *Diabetes Care*, *45*(Supplement_1), S125–S143. https://doi.org/10.2337/dc22-S009

American Diabetes Association Professional Practice Committee. (2022d). 10. Cardiovascular Disease and Risk Management: *Standards of Medical Care in Diabetes—2022*. *Diabetes Care*, *45*(Supplement_1), S144–S174. https://doi.org/10.2337/dc22-S010

American Diabetes Association Professional Practice Committee. (2022e). 11. Chronic Kidney Disease and Risk Management: *Standards of Medical Care in Diabetes—2022*. *Diabetes Care*, *45*(Supplement_1), S175–S184. https://doi.org/10.2337/dc22-S011

American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., … Gabbay, R. A. (2024). 2. Diagnosis and Classification of Diabetes: *Standards of Care in Diabetes—2024*. *Diabetes Care*, *47*(Supplement_1), S20–S42. https://doi.org/10.2337/dc24-S002

Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., Bocchi, E. A., Ponikowski, P., Perrone, S. V., Januzzi, J. L., Verma, S., Böhm, M., Ferreira, J. P., Pocock, S. J., Zannad, F., … On behalf of the EMPEROR-Reduced Trial Committees and Investigators. (2021). Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. *Circulation*, *143*(4), 337–349. https://doi.org/10.1161/CIRCULATIONAHA.120.051824

Barnes, J. A., Eid, M. A., Creager, M. A., & Goodney, P. P. (2020). Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *40*(8), 1808–1817. https://doi.org/10.1161/ATVBAHA.120.314595

Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. (2020). Type 2 Diabetes and its Impact on the Immune System. *Current Diabetes Reviews*, *16*(5), 442–449. https://doi.org/10.2174/1573399815666191024085838

Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D'Alessio, D. A., & Davies, M. J. (2020). 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, *43*(2), 487–493. https://doi.org/10.2337/dci19-0066

Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). *Diabetes & Metabolism*, *46*(2), 100–109. https://doi.org/10.1016/j.diabet.2019.101117

Chen, Y., Yang, D., Cheng, B., Chen, J., Peng, A., Yang, C., Liu, C., Xiong, M., Deng, A., Zhang, Y., Zheng, L., & Huang, K. (2020). Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. *Diabetes Care*, *43*(7), 1399–1407. https://doi.org/10.2337/dc20-0660

Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B. (2022). Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, *45*(11), 2753–2786. https://doi.org/10.2337/dci22-0034

De Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*, *45*(12), 3075–3090. https://doi.org/10.2337/dci22-0027

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Kosiborod, M., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., … Gabbay, R. A. (2023). 10. Cardiovascular Disease and Risk Management: *Standards of Care in Diabetes—2023*. *Diabetes Care*, *46*(Supplement_1), S158–S190. https://doi.org/10.2337/dc23-S010

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., … American Diabetes Association. (2023). 2. Classification and Diagnosis of Diabetes: *Standards of Care in Diabetes—2023*. *Diabetes Care*, *46*(Supplement_1), S19–S40. https://doi.org/10.2337/dc23-S002

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A. (2023a). 6. Glycemic Targets: *Standards of Care in Diabetes—2023*. *Diabetes Care*, *46*(Supplement_1), S97–S110. https://doi.org/10.2337/dc23-S006

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A. (2023b). 7. Diabetes Technology: *Standards of Care in Diabetes — 2023*. *Diabetes Care*, *46*(Supplement_1), S111–S127. https://doi.org/10.2337/dc23-S007

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A. (2023c). 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Care in Diabetes—2023*. *Diabetes Care*, *46*(Supplement_1), S140–S157. https://doi.org/10.2337/dc23-S009

Goldenberg, J. Z., Day, A., Brinkworth, G. D., Sato, J., Yamada, S., Jönsson, T., Beardsley, J., Johnson, J. A., Thabane, L., & Johnston, B. C. (2021). Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: Systematic review and meta-analysis of published and unpublished randomized trial data. *BMJ*, m4743. https://doi.org/10.1136/bmj.m4743

Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., Skyler, J. S., Snoek, F. J., Weinstock, R. S., & Peters, A. L. (2021). The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, *44*(11), 2589–2625. https://doi.org/10.2337/dci21-0043

Huang, I., Lim, M. A., & Pranata, R. (2020). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *14*(4), 395–403. https://doi.org/10.1016/j.dsx.2020.04.018

Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020). Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *14*(4), 535–545. https://doi.org/10.1016/j.dsx.2020.04.044

Lee, M. M. Y., Brooksbank, K. J. M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R. T., Berry, C., Chong, V., Coyle, L., Docherty, K. F., Dreisbach, J. G., Labinjoh, C., Lang, N. N., Lennie, V., McConnachie, A., Murphy, C. L., Petrie, C. J., Petrie, J. R., Speirits, I. A., … Sattar, N. (2021). Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). *Circulation*, *143*(6), 516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186

Shi, Q., Zhang, X., Jiang, F., Zhang, X., Hu, N., Bimu, C., Feng, J., Yan, S., Guan, Y., Xu, D., He, G., Chen, C., Xiong, X., Liu, L., Li, H., Tao, J., Peng, Z., & Wang, W. (2020). Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. *Diabetes Care*, *43*(7), 1382–1391. https://doi.org/10.2337/dc20-0598

Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *14*(4), 303–310. https://doi.org/10.1016/j.dsx.2020.04.004

Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *14*(3), 241–246. https://doi.org/10.1016/j.dsx.2020.03.011

Zelniker, T. A., Bonaca, M. P., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Budaj, A., Kiss, R. G., Padilla, F., Gause-Nilsson, I., Langkilde, A. M., Raz, I., Sabatine, M. S., & Wiviott, S. D. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes

Mellitus: Insights From the DECLARE-TIMI 58 Trial. *Circulation*, *141*(15), 1227–1234. https://doi.org/10.1161/CIRCULATIONAHA.119.044183

Zhang, Y., Lazzarini, P. A., McPhail, S. M., Van Netten, J. J., Armstrong, D. G., & Pacella, R. E. (2020). Global Disability Burdens of Diabetes-Related Lower-Extremity Complications in 1990 and 2016. *Diabetes Care*, *43*(5), 964–974. https://doi.org/10.2337/dc19-1614